Global Anemia Drugs Market Analysis 2022 to 2030

Global Anemia Drugs Market Analysis

$ 3999

The Global Anemia drugs market was valued at $15.98 Bn in 2022 and is estimated to expand at a CAGR of 8.9% from 2022-30 and will reach $31.6 Bn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Pieris Pharmaceuticals, GlaxoSmithKline, Amgen, Bayer AG, Biocon, Takeda Pharmaceutical, Sanofi, and bluebird bio among others.

ID: IN10GLPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Global AUTHOR: Nandini Shah

Buy Now

Global Anemia Drugs Market Executive Summary

The Global Anemia Drugs market was valued at $15.98 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 8.9% from 2022 to 2030 and will reach $31.6 Bn in 2030. Young children and pregnant women are most impacted by the significant Anemia global public health issue. According to WHO statistics, Anemia affects 40% of pregnant women and 42% of children under the age of five worldwide. In 2019, global Anemia prevalence was 29.9% of women aged 15-49, and 39.8% of children aged 0.5-4.5 years suffered from Anemia.

Anemia is a medical disorder when the hemoglobin or red blood cell (RBC) level is below normal. Some of the most common indications and symptoms of Anemia include fatigue, shortness of breath, dizziness, and palpitations. Anemia is divided into three categories. Excessive blood loss, which can happen during childbirth, menstruation, or loss of RBCs due to protracted bleeding, causes Anemia. Anemia can be caused by inadequate intake of nutrients including vitamins and minerals, which can also reduce or impair the production of red blood cells. This type of Anemia includes conditions including sickle cell Anemia, iron deficiency Anemia, and vitamin deficiency Anemia. The term "hemolytic Anemia" refers to the breakdown of red blood cells (RBCs) as a result of RBC fragility and inability to withstand the usual stresses placed on the circulatory system. The market for drugs to treat Anemia is expected to grow fast during the period of forecasting.

Market Dynamics

Market Growth Drivers

Chronic diseases, such as cancer, kidney disease, and HIV/AIDS, are major causes of anemia, and their increasing incidence is driving the demand for anemia drugs. Noncommunicable diseases (NCDs) account for 41 million annual fatalities, or 74% of all fatalities worldwide. 17 million people worldwide pass away from an NCD before they turn 70 each year; 86% of these untimely deaths take place in low- and middle-income nations. An aging population is more susceptible to anemia, due to the increased risk of chronic diseases and decreased ability to absorb nutrients from food. This is driving the growth of the anemia drugs market.

Increased awareness of anemia and its treatments is leading to early diagnosis and treatment, driving the demand for anemia drugs. Iron supplements are widely used to treat iron-deficiency anemia, and the increasing demand for these supplements is driving the growth of the anemia drugs market. Vitamin supplements, such as folic acid and Vitamin B12, are widely used to treat anemia caused by vitamin deficiencies. The increasing demand for these supplements is driving the growth of the anemia drugs market. The growing demand for home-based treatments, such as oral supplements and self-administered injections, is driving the growth of the anemia drugs market.

Market Restraints

Many anemia drugs, particularly erythropoietin-stimulating agents (ESAs), are expensive, which can limit their accessibility to patients. This is a major challenge in the market. The regulatory environment for anemia drugs is stringent, which can limit the entry of new players into the market and increase the cost of developing and bringing new drugs to market. Some anemia drugs, particularly ESAs, have been linked to serious side effects, such as cardiovascular events and tumor growth, which can limit their use and impact the market. Lack of awareness about anemia and its treatments, particularly in developing countries, is a major challenge in the market.

Competitive Landscape

Key Players

Pieris Pharmaceuticals
Acceleron Pharma
Amgen
Bayer AG
Biocon
Bluebird Bio
Takeda Pharmaceutical
Eli Lilly and Company
GlaxoSmithKline
GlycoMimetics
Regen Biopharma

Notable Deals

In 2021, Pfizer and BioNTech announced a collaboration to develop and commercialize a potential cure for sickle cell disease and β-thalassemia, two forms of hemoglobin disorders that can lead to Anemia.

Healthcare Policies and Regulatory Landscape

The regulatory body for the Anemia drugs market varies by country. However, some of the major regulatory bodies that oversee the approval and marketing of Anemia drugs include:

The Food and Drug Administration (FDA) is the primary regulatory body for the approval and marketing of drugs in the United States
European Medicines Agency (EMA) is the regulatory body for the approval and marketing of Anemia drugs in the European Union
The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) is the regulatory body for the approval and marketing of Anemia drugs in Japan
The Australian Therapeutic Goods Administration (TGA): The TGA is the regulatory body for the approval and marketing of Anemia drugs in Australia

Reimbursement Scenario

National healthcare systems can impact the extent to which Anemia drugs are covered by insurance and the cost burden that patients must bear. For example, in countries with universal healthcare systems, Anemia drugs may be more widely covered and more affordable for patients.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anemia Drugs Market Segmentation

By Type (Revenue, USD Billion):

Iron Deficiency
CKD (Chronic Kidney Disease)
Sickle Cell
Aplastic
Others

By Drugs

Dietary Supplements
Medicines

The types of nutritional supplements are further broken down into iron and vitamin supplements, among other categories, whilst the categories of medicines include antibiotics, hormones (erythropoietin), and chelation therapy (lead poisoning), among others.

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacy
Store Pharmacy
Online
Others

The distribution channel for anemia drugs in Global is complex and multifaceted. Pharmaceutical companies must work with a variety of stakeholders, including hospital and retail pharmacies, distributors, and regulatory authorities, to ensure that their products are effectively distributed to patients who need them.

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.